News Releases

Keyword Search

Jun-06-2023
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
May-31-2023
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
May-04-2023
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Apr-27-2023
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
Apr-13-2023
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
Apr-03-2023
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
Mar-27-2023
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mar-09-2023
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Mar-02-2023
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
Mar-01-2023
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)